Risk factors for malignant transformation of hepatocellular adenoma to hepatocellular carcinoma: protocol for systematic review and meta-analysis

被引:6
作者
Thevathasan, Tharusan [1 ]
Colbatzky, Teresa [2 ]
Schmelzle, Moritz [2 ]
Pratschke, Johann [2 ]
Krenzien, Felix [2 ]
机构
[1] Charite Univ Med Berlin, Dept Cardiol, Berlin, Germany
[2] Charite Univ Med Berlin, Dept Surg, Berlin, Germany
来源
BMJ OPEN | 2021年 / 11卷 / 08期
关键词
hepatology; hepatobiliary tumours; hepatobiliary disease; hepatobiliary surgery; risk management;
D O I
10.1136/bmjopen-2020-045733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Hepatocellular adenomas (HCAs) are solid liver tumours that are usually found incidentally during routine medical check-ups. Multiple modifiable and non-modifiable factors constitute a risk for the malignant transformation of HCAs to hepatocellular carcinoma (HCC), which has emerged to be one of the fastest growing causes of cancer-related mortality globally. This study protocol for a planned systematic review and meta-analysis documents the methodological approach to identify risk factors and their risk estimates for the transformation from HCA to HCC. Methods and analysis Two independent reviewers will systematically search and extract data from studies in patients of all ages published between January 1970 and June 2021 on PubMed, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Scopus Web of Science, Ovid, The Cochrane Hepatobiliary Group Controlled Trials Register and The Cochrane Central Register of Controlled Trials by using an a priori defined search strategy. Study quality will be rated with the National Institute of Health quality assessment tools. Disagreements will be resolved by consensus with a third independent reviewer. The primary outcome will be the odds ratio (OR) of developing HCC in patients with prediagnosed HCA depending on the exposure to risk factors. HCC diagnosis must be inferred based on imaging techniques or pathology. We will use R V.4.0.2 to conduct meta-analyses and generate pooled ORs based on random effects models. Results will be presented as forest plots. Cochran's Q and I-2 test will be performed to assess heterogeneity between included studies. Funnel plots and Egger's weighted regression will be used to evaluate publication bias. Ethics and dissemination No ethical approval is required as we will use and analyse data from previously published studies in which informed consent was obtained. The results will be disseminated in a peer-reviewed journal on completion.
引用
收藏
页数:6
相关论文
共 25 条
  • [1] GRADE guidelines: 3. Rating the quality of evidence
    Balshem, Howard
    Helfand, Mark
    Schuenemann, Holger J.
    Oxman, Andrew D.
    Kunz, Regina
    Brozek, Jan
    Vist, Gunn E.
    Falck-Ytter, Yngve
    Meerpohl, Joerg
    Norris, Susan
    Guyatt, Gordon H.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) : 401 - 406
  • [2] BAUM JK, 1973, LANCET, V2, P926
  • [3] EASL Clinical Practice Guidelines on the management of benign liver tumours
    Colombo, Massimo
    Forner, Alejandro
    Ijzermans, Jan
    Paradis, Valerie
    Reeves, Helen
    Vilgrain, Valerie
    Zucman-Rossi, Jessica
    [J]. JOURNAL OF HEPATOLOGY, 2016, 65 (02) : 386 - 398
  • [4] Liver Cell Adenoma: A Multicenter Analysis of Risk Factors for Rupture and Malignancy
    Deneve, Jeremiah L.
    Pawlik, Timothy M.
    Cunningham, Steve
    Clary, Bryan
    Reddy, Srinevas
    Scoggins, Charles R.
    Martin, Robert C. G.
    D'Angelica, Michael
    Staley, Charles A.
    Choti, Michael A.
    Jarnagin, William R.
    Schulick, Richard D.
    Kooby, David A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (03) : 640 - 648
  • [5] A Single-Center Surgical Experience of 122 Patients With Single and Multiple Hepatocellular Adenomas
    Dokmak, Safi
    Paradis, Valerie
    Vilgrain, Valerie
    Sauvanet, Alain
    Farges, Olivier
    Valla, Dominique
    Bedossa, Pierre
    Belghiti, Jacques
    [J]. GASTROENTEROLOGY, 2009, 137 (05) : 1698 - 1705
  • [6] LIVER-CELL ADENOMAS ASSOCIATED WITH USE OF ORAL-CONTRACEPTIVES
    EDMONDSON, HA
    HENDERSON, B
    BENTON, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (09) : 470 - 472
  • [7] European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  • [8] The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study
    Haring, Martijn P. D.
    Gouw, Annette S. H.
    de Haas, Robbert J.
    Cuperus, Frans J. C.
    de Jong, Koert P.
    de Meijer, Vincent E.
    [J]. LIVER INTERNATIONAL, 2019, 39 (05) : 905 - 913
  • [9] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]
  • [10] Kim Dong Hwan, 2009, Korean Journal of Internal Medicine, V24, P147, DOI 10.3904/kjim.2009.24.2.147